



The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation

Andrew J. Holland and Don W. Cleveland

Ludwig Institute for Cancer Research and Department of Cellular and Molecular Medicine, UCSD, La Jolla, California, USA.

The mitotic checkpoint plays an important role in preventing chromosome segregation errors and the production of aneuploid progeny. In this issue, Zhang et al. examine mice and cells lacking the deubiquitinating enzyme USP44. Surprisingly, they find that USP44 prevents chromosome segregation errors through a function independent of its previously identified role in the mitotic checkpoint. *Usp44*-null animals develop aneuploidy and experience increased rates of tumorigenesis, implicating USP44 as novel tumor suppressor.

Ubiquitination is a reversible posttranslational modification that regulates a broad range of cellular processes. Ubiquitin is a small, 76-amino-acid protein that can be covalently conjugated with the aid of ubiquitin ligases to cellular proteins and to itself to create divergent chains with differing lysine linkages. Substrates marked with a polymer of ubiquitin molecules are often targeted for destruction by the 26S proteasome. Ubiquitin ligases are counterbalanced by deubiquitinases (DUBs) that remove molecules of ubiquitin previously added to target proteins. Despite their importance in controlling protein homeostasis, the substrates and physiological functions of most DUBs remain unknown (1). In this issue, Zhang et al. examine the role of the DUB ubiquitin-specific protease 44 (USP44) in ensuring accurate chromosome segregation and uncover a novel role of this enzyme as a tumor suppressor (2).

Dividing the genome

Each time a cell divides, it must partition its replicated genome to ensure that each new daughter cell receives a single copy of every chromosome. Aneuploidy, or an abnormal chromosome number, arises from errors in chromosome segregation during mitosis and is a remarkably common characteristic of human cancers. More than a decade ago aneuploidy was proposed to promote tumorigenesis, but current evidence suggests that its role is complex, both promoting and inhibiting

tumorigenesis, depending on the genetic context in which it is found (3).

Aneuploidy often arises as a consequence of an underlying chromosomal instability (CIN), a condition characterized by frequent and continuing chromosome segregation errors during division (4). A major safeguard to protect against CIN is the mitotic checkpoint (also known as the spindle assembly checkpoint), a surveillance mechanism that operates in every division to prevent chromosome segregation errors and the resultant aneuploidy (5). In mitosis, a bipolar microtubule spindle apparatus forms to segregate chromosomes into the daughter cells. Chromosomes attach to microtubules of the mitotic spindle at a proteinaceous complex known as the kinetochore. Unattached kinetochores release an inhibitory signal that culminates in the creation of a protein complex that binds to CDC20 and prevents its activation of the anaphase-promoting complex (APC), an E3 ubiquitin ligase (Figure 1). Following attachment of all kinetochores to spindle microtubules, the mitotic checkpoint is silenced and APC^{CDC20} ubiquitinates cyclin B1 and securin, targeting them for proteasomal degradation, leading to anaphase onset with separation of the duplicated sister chromosomes, followed by mitotic exit.

Breaking the chains: USP44's role in regulating mitosis

An shRNA screen for components of the ubiquitin pathway that are involved in mitotic checkpoint signaling uncovered the DUB USP44 (6). USP44-depleted cells underwent premature entry into anaphase in unperturbed cell cycles and were unable

to sustain activation of the mitotic checkpoint in the presence of spindle toxins. This points to a role of USP44 in inhibiting or antagonizing the activity of APC^{CDC20}. The simplest model is that USP44 deubiquitinates APC^{CDC20} substrates, such as securin and cyclin B1. However, further analysis has suggested a more direct role of USP44 in the mitotic checkpoint: Since polyubiquitination of CDC20 is thought to be required to activate checkpoint-inhibited APC^{CDC20}, the conventional view is that USP44 restrains APC^{CDC20} activity by stripping ubiquitin molecules from CDC20 to maintain inhibition by the mitotic checkpoint (6). Aspects of this model have remained controversial, however (7, 8), and the precise mechanism(s) by which USP44 functions in the mitotic checkpoint was imprecisely defined.

In this issue, Zhang et al. explore the physiological function of USP44 by creating a mouse model possessing a null allele of the gene (2). Surprisingly, given that mitotic abnormalities are observed in cultured cells depleted of USP44 (6), Zhang et al. found that *Usp44*^{-/-} mice were born at normal frequencies and displayed no apparent defects (2). Since proper functioning of the mitotic checkpoint is required for viability in mammals, this demonstrates that USP44 is not an indispensable component of this checkpoint in mammals (9).

MEFs derived from *Usp44*^{-/-} animals did, however, exhibit a subtle defect in mitotic checkpoint signaling: *Usp44*^{-/-} MEFs displayed a reduced duration of mitotic arrest in the presence of spindle toxins and progressed through unchallenged divisions more rapidly. Zhang et al. found that MEFs lacking USP44 also exhibit an increase in the rate of chromosome segregation errors and whole chromosome aneuploidy, but notably show no evidence of structural alterations in chromosomes (2). The simple explanation is that the mitotic checkpoint defect is responsible for the chromosome segregation errors in *Usp44*^{-/-} cells. This simple interpretation, however, is wrong: further experiments demonstrated that

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest.* doi:10.1172/JCI66420.




Figure 1

Loss of USP44 leads to errors in chromosome segregation. *Usp44^{+/+}* cells: Centrosomes separate in prophase to instruct the formation of a bipolar microtubule spindle apparatus. Chromosomes attach to microtubules of the mitotic spindle at their kinetochores. Unattached kinetochores create a diffusible mitotic checkpoint signal that culminates in the inhibition of the E3 ligase activity of APC^{CDC20}. At metaphase when all kinetochores are correctly attached to microtubules of the spindle, the mitotic checkpoint is turned off and APC^{CDC20} ubiquitinates securin and cyclin B1 to target them for destruction by the 26S proteasome. Securin destruction promotes sister chromatid disjunction, while cyclin B1 destruction promotes mitotic exit. *Usp44^{-/-}* cells: Incomplete centrosome separation prior to nuclear envelope breakdown creates a spindle geometry that predisposes to the formation of improper kinetochore-microtubule interactions. The close positioning of the two centrosomes leads to an increase in the formation of merotelic kinetochore attachments (where a single kinetochore attaches to two different centrosomes) (14). These attachments persist into anaphase, resulting in lagging anaphase chromosomes and chromosome missegregation.

delaying mitotic progression with low doses of an APC inhibitor reduced chromosome segregation errors in cells with a bona fide mitotic checkpoint defect (cells heterozygous for the checkpoint component *Mad2*; ref. 10), but failed to prevent segregation errors in cells lacking USP44. This finding suggests that the subtle checkpoint defect observed in *Usp44^{-/-}* cells is not responsible for the CIN in cells lacking the enzyme.

A role in the mitotic checkpoint and beyond

If a mitotic checkpoint defect is not the cause, then what is the mechanism by which loss of USP44 leads to an increased rate of chromosome segregation errors and aneuploidy? The first clue came from the analysis of how cells lacking USP44 missegregated their chromosomes. By far the most frequent mitotic error in *Usp44^{-/-}* MEFs was an increased frequency of lagging anaphase chromosomes. Lagging chromosomes are caused by the aberrant attachment of a single kinetochore to spindle microtubules emanating from more than one spindle pole. This configuration, known as a merotelic attachment, causes the affected chromosome to be pulled by microtubules anchored to



opposite spindle poles, causing them to “lag” in the spindle midzone while the correctly attached chromosomes move poleward during anaphase (11). Several mitotic abnormalities have been shown to increase the rate of formation of merotelic attachments, including centrosome amplification (12, 13) and the incomplete separation of centrosomes prior to nuclear envelope breakdown (NEBD) (14). Consistent with the latter possibility, *Usp44*^{-/-} MEFs display abnormal spindle geometries and reduced centrosome separation at NEBD. Live-cell imaging revealed a strong correlation between the presence of an initial spindle defect and subsequent anaphase chromosome segregation errors. The current evidence, therefore, suggests that chromosome segregation errors in *Usp44*^{-/-} cells do not arise from mitotic checkpoint abnormalities as expected, but rather stem from incomplete centrosome separation that predisposes cells to the development of increased numbers of merotelic attachments (Figure 1).

An obvious question raised by these findings is, how does USP44 function to promote centrosome separation? Insight into the mechanism came from the identification of a previously overlooked pool of USP44 that is localized to the centrosome during interphase. Zhang and colleagues identified a domain in USP44 that is required for direct interaction with the centrosome component centrin and recruitment of USP44 to the centrosome. To address the physiological function of the centrin-USP44 complex in chromosome segregation, the authors analyzed the ability of USP44 mutants to rescue the mitotic defects of *Usp44*^{-/-} cells. As expected, expression of exogenous wild-type USP44 rescued the spindle defects and lagging anaphase chromosomes in *Usp44*^{-/-} MEFs; however, complementation with a point mutant of USP44 unable to bind centrin or a catalytically inactive USP44 mutant failed to mitigate either defect. Therefore, the deubiquitinating activity and an ability to interact with centrin are both critical for USP44's function in ensuring accurate chromosome segregation. Interestingly, a proportion of centrin also localizes to the nucleus of cells, where it forms a complex required for nucleotide excision repair following DNA damage (15). It will be interesting to establish whether USP44 is a binding partner of the nuclear pool of centrin and whether this interaction is required for centrin's function in nucleotide excision repair.

USP44 DUBbed a tumor suppressor

Increased levels of aneuploidy were observed in the spleens of *Usp44*^{-/-} animals, prompting an analysis of whether animals lacking the DUB were tumor-prone. Indeed, Zhang et al. found that aged *Usp44*^{-/-} mice had an approximately fivefold-increased incidence of spontaneously arising tumors, thus identifying USP44 as a novel tumor suppressor (2). Adenomas of the lung were the most common tumors identified, with an approximately ninefold increase in *Usp44*^{-/-} animals relative to controls. Reduced expression of USP44 was also observed in human lung adenocarcinoma, and patients with low levels of the enzyme had a significantly reduced overall survival.

While it is tempting to conclude that the aneuploidy induced by loss of USP44 is responsible for promoting tumor formation, current evidence from other mouse models of CIN have shown that the degree of aneuploidy in cells and tissue is a poor predictor of tumor susceptibility in mice (9). Indeed, there are several mouse CIN models without an increase in spontaneous tumor formation that exhibit similar or greater levels of aneuploidy compared with that observed in *Usp44*^{-/-} animals (9). Thus, it is plausible that loss of USP44 causes defects in addition to mitotic chromosome segregation errors that predispose animals to tumor development. For instance, USP44 has been shown to prevent embryonic stem cell differentiation by negatively regulating histone H2B monoubiquitination (16). USP44 is likely to have numerous targets, and a complete inventory of all of the enzyme's substrates will aid our future understanding of its tumor suppressor function.

Future directions

The work by Zhang and colleagues (2) provides new insights into the physiological function of USP44 and the impact that loss of this DUB has on mitosis and cancer susceptibility. These discoveries raise a slew of unanswered questions, including: How does the USP44-centrin complex promote centrosome separation prior to NEBD? What role does USP44's enzymatic activity play in this process? What are the substrates of USP44, and how is the substrate specificity or function of the enzyme altered by post-translational modifications, interacting proteins, and subcellular localization? What are the critical functions of USP44 that are required for tumor suppression?

Finally, although aneuploidy is commonly associated with cancer, a disease of unremitting cell growth, yeast and mouse cells that are aneuploid for a single chromosome exhibit a proteotoxic stress that reduces their growth rate in culture (17, 18). In the context of tumors, aneuploidy is likely to occur alongside additional “aneuploidy-tolerating” mutations. A recent genetic screen for mutations that improve the proliferative potential of aneuploid yeast cells identified mutations in the deubiquitinating enzyme *UBP6*, demonstrating the importance of the ubiquitin-proteasome pathway in suppressing the growth of aneuploid cells (19). An interesting question for future study is whether loss of USP44 facilitates the proliferation of aneuploid cells. Identifying the lesions that collaborate with aneuploidy to promote tumor formation is one key area for future research.

Acknowledgments

We thank Quan Zhu for helpful comments on this preview. We apologize to all whose work was not cited because of space restrictions. This work was supported by a grant (GM29513) from the NIH to D.W. Cleveland, who receives salary support from the Ludwig Institute for Cancer Research. A.J. Holland is supported by a Leukemia and Lymphoma Society special fellowship.

Address correspondence to: Andrew J. Holland or Don Cleveland, University of California San Diego, CMM-E 3080, 9500 Gilman Drive, Ludwig Institute, La Jolla, CA 92093-0670, USA. Phone: 858.534.7899; Fax: 858.534.7659; E-mail: a1holland@ucsd.edu (A.J. Holland). Phone: 858.534.7811; Fax: 858.534.7659; E-mail: dcleveland@ucsd.edu (D. Cleveland).

1. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol*. 2009;10(8):550–563.
2. Zhang Y, et al. USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis. *J Clin Invest*. 2012;122(12):4362–4374.
3. Holland AJ, Cleveland DW. Losing balance: the origin and impact of aneuploidy in cancer. *EMBO Rep*. 2012;13(6):501–514.
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature*. 1997;386(6625):623–627.
5. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. *Nat Rev Mol Cell Biol*. 2007;8(5):379–393.
6. Stegmeier F, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. *Nature*. 2007;446(7138):876–881.
7. Nilsson J, Yekezare M, Minshull J, Pines J. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. *Nature Cell Biol*.



- 2008;10(12):1411–1420.
8. Varetto G, Guida C, Santaguida S, Chiroli E, Musacchio A. Homeostatic control of mitotic arrest. *Mol Cell*. 2011;44(5):710–720.
 9. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. *Nat Rev Mol Cell Biol*. 2009;10(7):478–487.
 10. Michel LS, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. *Nature*. 2001;409(6818):355–359.
 11. Cimini D. Merotelic kinetochore orientation, aneuploidy, and cancer. *Biochim Biophys Acta*. 2008;1786(1):32–40.
 12. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. *Nature*. 2009;460(7252):278–282.
 13. Silkworth WT, Nardi IK, Scholl LM, Cimini D. Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. *PLoS One*. 2009;4(8):e6564.
 14. Silkworth WT, Nardi IK, Paul R, Mogilner A, Cimini D. Timing of centrosome separation is important for accurate chromosome segregation. *Mol Biol Cell*. 2012;23(3):401–411.
 15. Araki M, et al. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair. *J Biol Chem*. 2001;276(22):18665–18672.
 16. Fuchs G, et al. RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. *Mol Cell*. 2012;46(5):662–673.
 17. Torres EM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. *Science*. 2007;317(5840):916–924.
 18. Williams BR, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. *Science*. 2008;322(5902):703–709.
 19. Torres EM, et al. Identification of aneuploidy-tolerating mutations. *Cell*. 2010;143(1):71–83.

Mitochondrial heme: an exit strategy at last

Mark D. Fleming¹ and Iqbal Hamza²

¹Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ²Department of Animal and Avian Sciences, Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, USA.

The transport of heme across membranes is critical for iron absorption, the formation of hemoglobin and other hemoproteins, and iron recycling in macrophages. However, the identity of heme transport proteins has been elusive. In this issue of the *JCI*, Chiabrando et al. reveal that an isoform of the feline leukemia virus subgroup C receptor (FLVCR1) exports heme from the mitochondria and is critical for erythroid differentiation.

Nearly two-thirds of the body's iron endowment is in the form of hemoglobin in erythrocytes, and each erythrocyte contains more than a billion iron atoms in the form of heme (1). Consequently, it is not surprising that inherited or acquired defects in hemoglobin synthesis, including the thalassemias, hemoglobinopathies, and iron deficiency, are among the most prevalent human diseases. Importantly, the approximately 360 billion erythrocytes produced daily require over 250 mg of heme to assemble into hemoglobin. Heme is synthesized in the mitochondria, but globin is translated in the cytosol, and it is unclear how newly synthesized heme is transported out of the mitochondria for incorporation into hemoglobin (2). Heme transport across membranes is important for dietary iron absorption and crucial for erythrocyte heme iron recycling in the reticuloendothelial system (RES) macrophage. Despite the physiologic importance of these processes, the molecular pathways of transmembrane heme transport have, for the most part, remained obscure, in large part due to technical difficulties in identifying heme-specific transporters in

mammalian cells and the inability to translate these findings to whole organisms. In this issue of the *JCI*, using a combination of siRNA studies and targeted mutations in mice, Chiabrando et al. provide compelling evidence that an isoform of the feline leukemia virus subgroup C receptor (FLVCR1) exports heme from the mitochondria (3).

The requirement for heme transport

For more than 50 years, it has been known that nutritional heme-iron is absorbed in the intestine by an active, energy-dependent, and inducible process that requires a heme transporter in enterocytes. This is because elemental iron has limited bioavailability in the intestine due to the presence of natural iron chelators, such as phytates and tannins, as well as its tendency to oxidize (i.e., to rust) and precipitate. In contrast, even though heme-iron constitutes only one-third of total dietary iron, it is more easily absorbed and is the source for two-thirds of body iron in meat-eating individuals (4). This is a consequence of heme's solubility at intestinal pH and because its uptake is not known to be influenced by other dietary factors.

Heme must also be transported across mitochondrial membranes because the final steps of heme synthesis occur in the mitochondria, but some hemoproteins such as hemoglobin are cytosolic (2). Like-

wise, heme transport out of phagolysosomes is an essential component of iron recycling by macrophages, as heme oxygenase (Hmox), the enzyme that catalyzes the oxidation of heme to biliverdin, carbon monoxide, and ferric iron, is found largely tethered to the cytosolic surface of the endoplasmic reticulum (5). Iron recycling out of the macrophage is mediated by the ferrous iron exporter ferroportin (FPN1) (6), whose cell-surface expression is tightly controlled by the systemic iron regulatory hormone hepcidin (7). In this manner, iron catabolized by RES macrophages from heme can be released immediately to the plasma to replenish the Fe₂-Tf pool necessary for erythropoiesis or stored as ferritin for subsequent use.

Mammalian heme transporters

The identification and characterization of heme and other porphyrin transporters in mammals has proven to be difficult (2), in part due to a lack of genetic and molecular tools, but also as a consequence of the promiscuity of proteins capable of transporting heme with low affinity. Furthermore, in vivo investigation of transporter proteins identified in vitro or on the basis of their expression pattern has been misleading or has provided ambiguous results. For example, Hcp1, a putative apical intestinal heme importer, was eventually proven to be essential for folate transport in the intestine when it was found to be mutated in patients with congenital folate deficiency (8, 9). Whether Hcp1 also contributes to the absorption of heme in the intestine is uncertain at this time. Some evidence suggests that the breast cancer

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest*. doi:10.1172/JCI66607.